References
- Agência Brasil. (2023). Governo prevê R$ 42 bi em investimento no complexo industrial de saúde. https://agenciabrasil.ebc.com.br/politica/noticia/2023-09/governo-preve-r-42-bi-em-investimento-no-complexo-industrial-de-saude.
- Agência de Notícias das Hepatites. (2018). O Grupo Otimismo solicitará ao TCU uma auditoria nas Parcerias de Desenvolvimento Produtivo (PDPs). https://hepato.com/2018/10/14/o-grupo-otimismo-solicitara-ao-tcu-uma-auditoria-nas-parcerias-de-desenvolvimento-produtivo/.
- Agência Fiocruz. (2019). Fiocruz esclarece sobre contratos de PDPs. https://agencia.fiocruz.br/fiocruz-esclarece-sobre-contratos-de-pdps?fbclid=IwAR2htkkrkmPImW9DciIeW1Rm4G_n2GYQnP7ePzk9090Noen8zfE4dwHWb1M.
- Assefa, Y., Hill, P. S., Ulikpan, A., & Williams, O. D. (2017). Access to medicines and hepatitis C in Africa: Can tiered pricing and voluntary licencing assure universal access, health equity and fairness? Globalization and Health, 13(1), 73. https://doi.org/10.1186/s12992-017-0297-6
- Benchimol, J. (2017). Yellow fever vaccine in Brazil: Fighting a tropical scourge, modernising the nation. In C. Holmberg, S. Blume, & P. Greenough (Eds.), The politics of vaccination: A global history (pp. 174–208). Manchester University Press.
- Benzaken, A. S. (2019). Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach. The Brazilian Journal of Infectious Diseases, 23(3), 182–190. https://doi.org/10.1016/j.bjid.2019.04.010. Epub 2019 May 27. PMID: 31145876.
- Brennan, T., & Shrank, W. (2014). New expensive treatments for hepatitis C infection. Journal of the American Medical Association, 312(6), 593–594. https://doi.org/10.1001/jama.2014.8897. PMID: 25038617.
- Caliari, T., & Ruiz, R. M. (2014). Brazilian pharmaceutical industry and generic drugs policy: Impacts on structure and innovation and recent developments. Science and Public Policy, 41(2), 245–256. https://doi.org/10.1093/scipol/sct053
- Camargos and Moreira. (2015). Compras para a Inovação no Ministério da Saúde – no Discurso, Sim; na Licitação, Não. Journal of Accounting, Management and Governance, 18(3).
- Cassier, M., & Correa, M. (2018). A consortium in times of crisis: Producing Brazilian sofosbuvir? (2014-2017). In M. Cassier, & M. Correa (Eds.), Health innovation and social justice in Brazil. Palgrave MacMillan.
- Chataway, J., Banda, G., Cochrane, G., & Manville, C. (2016). Innovative procurement for health and industrial development. In M. Mackintosh, G. Banda, W. Wamae, & P. Tibandebage (Eds.), Making medicines in Africa: The political economy of industrializing for local health (pp. 243–260). Palgrave Open. http://www.palgrave.com/us/book/9781137546463.
- Chaudhuri, S. (2022). COVID-19 vaccines, patent barriers and local production in developing countries. SSRN, http://doi.org/10.2139/ssrn.4293565
- Chaudhury, S. (2005). The WTO and India's pharmaceuticals industry: patent protection, TRIPS and developing countries. New Delhi: Oxford University Press.
- Conitec (Comissão Nacional de Incorporação de Tecnologias no SUS). (2018). Sofosbuvir em associação a velpatasvir para hepatite C crônica. Relatório de Recomendação. https://www.gov.br/conitec/pt-br/midias/relatorios/relatorio_sofosbuvirvelpatasvir_hepatitec_cronica.pdf.
- Coutinho, C., et al. (2021). Hepatite C no Brasil: panorama atual e desafios em face à pandemia de COVID-19. https://hdl.handle.net/10438/30238.
- DNDi. (2018). Pharmaceutical companies and non-profits team up to provide affordable hepatitis C treatment in Latin America. Available at: https://dndi.org/press-releases/2018/pharmaceutical-companies-nonprofits-team-up-affordable-hepc-treatment-latin-america/.
- Dong, J., & Mirza, Z. (2016). Supporting the production of pharmaceuticals in Africa. Bulletin of the World Health Organization, 94(1), 71–72. https://doi.org/10.2471/BLT.15.163782
- Douglass, C. H., Pedrana, A., Lazarus, J. V., ‘t Hoen, E. F. M., Hammad, R., Leite, R. B., Hill, A., & Hellard, M. (2018). Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Medicine, 16(1), 175. https://doi.org/10.1186/s12916-018-1162-z
- Eimer, T. and Lutz, S. (2010). Developmental states, civil society, and public health: Patent regulation for HIV/AIDS pharmaceuticals in India and Brazil. Regulation and Governance. Vol. 4, Issue 2. https://doi.org/10.1111/j.1748-5991.2010.01074.x
- Estado de SP. (2018). Justiça concede quebra de patente de remédio contra hepatite C. https://www.estadao.com.br/saude/justica-concede-quebra-de-patente-de-remedio-contra-hepatite-c/.
- Fiocruz. (2023). Fiocruz amplia as opções de tratamento da hepatite C no Brasil. https://portal.fiocruz.br/noticia/fiocruz-amplia-opcoes-de-tratamento-da-hepatite-c-no-brasil.
- Fleury, S. (2011). Brazil's health-care reform: Social movements and civil society. Lancet. 377(9779):1724-1725. https://doi.org/10.1016/S0140-6736(11)60318-8
- Flynn, M. B. (2015). Pharmaceutical Autonomy and Public Health in Latin America: State, Society and Industry in Brazil’s AIDS Program (1st edition). Routledge.
- Folha de São Paulo. (2018a). Em guerra bilionária, farmacêutica tenta barrar genérico contra hepatite C. https://www1.folha.uol.com.br/cotidiano/2018/09/em-guerra-bilionaria-farmaceutica-tenta-barrar-generico-contra-hepatite-c.shtml.
- Folha de São Paulo. (2018b). Liminar barra entrega de genéricos contra hepatite C para 15 mil pacientes. https://www1.folha.uol.com.br/cotidiano/2018/12/liminar-barra-entrega-de-genericos-contra-hepatite-c-para-15-mil-pacientes.shtml.
- Fonseca, E. M., Shadlen, K., & Bastos, F. I. (2019). Integrating science, technology and health policies in Brazil: incremental change and public health professionals as agents of reform. Journal of Latin American Studies, 51(2), 357–377. https://doi.org/10.1017/S0022216X18001050
- Fonseca, E. M., Shadlen, K. C., & Moraes Achcar, H. (2023). Vaccine technology transfer in a global health crisis: Actors, capabilities, and institutions. Research Policy, 52(4), https://doi.org/10.1016/j.respol.2023.104739
- Ford, N., Wilson, D., Chaves, G. C., Lotrowska, M., & Kijtiwatchakul, K. (2007). Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. Aids (london, England), 21(Suppl 4), S21–S29. https://doi.org/10.1097/01.aids.0000279703.78685.a6. PMID: 17620749.
- Gadelha, C. (2003). O complexo industrial da saúde e a necessidade de um enfoque dinâmico na economia da saúde. Ciência & Saúde Coletiva, 8(2), 521. https://doi.org/10.1590/S1413-81232003000200015
- Gilead. (2014). Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C treatments in developing countries. Press Release.
- Governo da Bahia. (2015). Bahiafarma produzirá medicamentos para tratamento de HIV e hepatite C. http://www.saude.ba.gov.br/2015/08/12/bahiafarma-produzira-remedios-para-tratamento-de-hiv-e-hepatite-c/.
- Governo de Pernambuco. (2018). Lafepe produzirá medicamentos para hepatite C e esclerose múltipla. https://www.lafepe.pe.gov.br/noticias/lafepe-produzira-medicamentos-para-hepatite-c-e-esclerose-multipla.
- GTPI. (2016). Produção nacional do sofosbuvir como alternativa para ampliação do acesso à cura da hepatite C. https://deolhonaspatentes.org/wp-content/uploads/2016/06/GTPI_notasobreproducaolocalsofosbuvir.pdf.
- Homma, A., et al. (2005). Desenvolvimento e produção de vacinas no Instituto de Tecnologia em Imunobiológicos (Bio-manguinhos) da Fiocruz. In P. Buss, J. Temporão, & J. Carvalheiro (Eds.), Vacinas, soros e imunizações no Brasil. Ed. Fiocruz.
- Homma, A., Tanuri, A., Duarte, A. J. S., Marques, E., de Almeida, A., Martins, R., Silva-Junior, J. B., & Possas, C. (2013). Vaccine research, development, and innovation in Brazil: A translational science perspective. Vaccine, 31(Suppl 2), B54–B60. https://doi.org/10.1016/j.vaccine.2012.11.084
- Kale, D., & Little, S. (2007). From imitation to innovation: The evolution of R&D capabilities and learning processes in the Indian pharmaceutical industry. Technology Analysis 589–609. https://doi.org/10.1080/09537320701521317
- Kumraj, G., Pathak, S., Shah, S., Majumder, P., Jain, J., Bhati, D., Hanif, S., Mukherjee, S., & Ahmed, S. (2022). Capacity building for vaccine manufacturing across developing countries: The way forward. Human Vaccines & Immunotherapeutics, 18(1), 1. https://doi.org/10.1080/21645515.2021.2020529
- Lander, B., & Thorsteinsdóttir, H. (2011). Developing biomedical innovation capacity in India. Science and Public Policy, 38(10), 767–781. https://doi.org/10.3152/030234211X13070021633080
- Mackintosh, M., Banda, G., Tibandebage, P., and Wamae, W. (2016). Making medicines in Africa: The political economy of industrializing for local health. Palgrave Open. http://www.palgrave.com/us/book/9781137546463.
- Mayberry, J., & Lee, W. (2019). The revolution in treatment in Hepatitis C. Medical Clinics of North America, 103(1), 43–55. https://doi.org/10.1016/j.mcna.2018.08.007. PMID: 30466675.
- Mesquita, F., Santos, M. E., Benzaken, A, Corrêa, R. G., Cattapan, E., Sereno, L. S., and Naveira, M. C. M. (2016). The Brazilian comprehensive response to hepatitis C: From strategic thinking to access to interferon-free therapy. BMC Public Health, 16(1), 1132. https://doi.org/10.1186/s12889-016-3784-4
- Ministério da Saúde. (2010). Mais saúde: direito de todos: 2008–2011 (4a edição).
- Ministério da Saúde. (2018). Plano para eliminação da Hepatite C no Brasil. Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das IST, do HIV/Aids e das Hepatites Virais. http://www.aids.gov.br/pt-br/pub/2019/plano-para-eliminacao-da-hepatite-c-no-brasil.
- Ministério da Saúde. (2019). Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções. 1ª edição.
- Movimento Brasileiro de Luta Contra as Hepatites Virais. (2018). Carta ao ministro da saúde solicitando compra emergencial de medicamentos para hepatite C. https://mbhv.org.br/2018/10/04/carta-ao-ministro-da-saude-solicitando-compra-emergencial-de-medicamentos-para-hepatite-c/.
- Mujinja, P. G. M., Mackintosh, M., Justin-Temu, M., and Wuyts, M. (2014). Local production of pharmaceuticals in Africa and access to essential medicines. Globalization & Health, 10(12), 1–12.
- Nunn, A. et al. (2007, November). Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. Plos Medicine, 4(11), e305.
- Nunn, A. (2009). The politics and history of AIDS treatment in Brazil. Springer Press.
- Pollack, A. (2015). High Cost of Sovaldi Hepatitis C Drug Prompts a Call to Void Its Patents. New York Times. https://www.nytimes.com/2015/05/20/business/high-cost-of-hepatitis-c-drug-prompts-a-call-to-void-its-patents.html.
- Russo, G., & Banda, G. (2015). Re-thinking pharmaceutical production in Africa: Insights from the analysis of the local manufacturing dynamics in Mozambique and Zimbabwe. Studies in Comparative International Development, 50(2), 258–281. https://doi.org/10.1007/s12116-015-9186-2
- Russo, G. and Oliveira, L. D. (2016). South-South collaboration in pharmaceuticals: Manufacturing anti-retroviral medicines in Mozambique. In M. Mackintosh (Ed.), Making medicines in Africa: The political economy of industrializing for local health (pp. 85–102). Palgrave Open. http://www.palgrave.com/us/book/9781137546463.
- Santos, M. L. (2023). Fiocruz assina acordo para registro de medicamento para hepatite C na Anvisa. Portal Fundação Oswaldo Cruz.: https://portal.fiocruz.br/noticia/fiocruz-assina-acordo-para-registro-de-medicamento-para-hepatite-c-na-anvisa.
- Shadlen, K. C., & Fonseca, E. M. (2013). Health Policy as Industrial Policy: Brazil in Comparative Perspective. Politics & Society, 41(4), 561–587. https://doi.org/10.1177/0032329213507552
- Sidibé, M., Yong, L., & Chan, M. (2014). Commodities for better health in Africa: Time to invest locally. Bulletin of the World Health Organization, 92(6), 387–387A. https://doi.org/10.2471/BLT.14.140566
- Simonetti, R. et al. (2016). Pharmaceuticals in Kenya: The evolution of technological capabilities. In Mackintosh, M. et al. Making medicines in Africa: The political economy of industrializing for local health (pp. 25-44). Palgrave Open. http://www.palgrave.com/us/book/9781137546463.
- Souza Lima, R. T. (2019). Austerity and the future of the Brazilian Unified Health System (SUS): Health in perspective. Health Promotion International, 34(Supplement).
- Sundfeld, C. A., & Souza, R. P. d. (2013). Parcerias para o desenvolvimento produtivo em medicamentos e a Lei de Licitações. Revista De Direito Administrativo, 264, 91–133. https://doi.org/10.12660/rda.v264.2013.14078
- Tibandebage, P. et al. (2016). Pharmaceutical Manufacturing Decline in Tanzania: How Possible Is a Turnaround to Growth?. In Mackintosh, M. et al. Making medicines in Africa: The political economy of industrializing for local health. (pp. 45-64). Palgrave Open. http://www.palgrave.com/us/book/9781137546463.
- Varrichio, P. (2017). As Parcerias para o desenvolvimento produtivo da saúde. In T. Rauen (Ed.), Políticas de Inovação pelo Lado da Demanda no Brasil. Ipea.
- World Health Organization. (2021). World local production forum: Enhancing access to medicines and other health technologies: Report of the First WLPF. https://apps.who.int/iris/handle/10665/343393.
- World Health Organization. (2023). “Health for All: Transforming economies to deliver what matters. Final Report: https://www.who.int/publications/m/item/health-for-all–transforming-economies-to-deliver-what-matters.